These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 29929111

  • 1. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis.
    Zhang MN, Zou LP, Wang YY, Pang LY, Ma SF, Huang LL, Gao Y, Lu Q, Franz DN.
    Seizure; 2018 Aug; 60():86-90. PubMed ID: 29929111
    [Abstract] [Full Text] [Related]

  • 2. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P.
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE, Rietman AB, Bindels-de Heus K, Looman CW, Rizopoulos D, Sibindi TM, Cherian PJ, Jansen FE, Moll HA, Elgersma Y, de Wit MC.
    Neurology; 2016 Sep 06; 87(10):1011-8. PubMed ID: 27511181
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L, Liu Y, Pang L, Ju J, Shi Z, Zhang J, Chen X, Su X, Hu L, Shi X, Yang X.
    Zhonghua Er Ke Za Zhi; 2014 Nov 06; 52(11):812-6. PubMed ID: 25582464
    [Abstract] [Full Text] [Related]

  • 5. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A.
    Epilepsy Behav; 2019 Feb 06; 91():94-98. PubMed ID: 29941212
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP, Krueger DA.
    Neuro Oncol; 2015 Dec 06; 17(12):1550-9. PubMed ID: 26289591
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N, Han L, Wong M.
    Epilepsia; 2015 Jul 06; 56(7):1088-97. PubMed ID: 26122303
    [Abstract] [Full Text] [Related]

  • 11. The use of rapamycin in patients with tuberous sclerosis complex: Long-term results.
    Canpolat M, Gumus H, Kumandas S, Coskun A, Per H.
    Epilepsy Behav; 2018 Nov 06; 88():357-364. PubMed ID: 30305233
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.
    He W, Chen J, Wang YY, Zhang MN, Qian-Lu, Wang QH, Luo XM, Chen XQ, Zou LP.
    Seizure; 2020 Jul 06; 79():20-26. PubMed ID: 32416565
    [Abstract] [Full Text] [Related]

  • 14. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
    Aronica E, Specchio N, Luinenburg MJ, Curatolo P.
    Brain; 2023 Jul 03; 146(7):2694-2710. PubMed ID: 36806388
    [Abstract] [Full Text] [Related]

  • 15. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep 03; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 16. Epilepsy treatment patterns among patients with tuberous sclerosis complex.
    Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S.
    J Neurol Sci; 2018 Aug 15; 391():104-108. PubMed ID: 30103955
    [Abstract] [Full Text] [Related]

  • 17. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN.
    Ann Neurol; 2013 Nov 15; 74(5):679-87. PubMed ID: 23798472
    [Abstract] [Full Text] [Related]

  • 18. Epileptic spasms in tuberous sclerosis complex.
    Hsieh DT, Jennesson MM, Thiele EA.
    Epilepsy Res; 2013 Sep 15; 106(1-2):200-10. PubMed ID: 23796861
    [Abstract] [Full Text] [Related]

  • 19. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
    Guo D, Zhang B, Han L, Rensing NR, Wong M.
    Epilepsia; 2024 Feb 15; 65(2):483-496. PubMed ID: 38049961
    [Abstract] [Full Text] [Related]

  • 20. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P, Moavero R, van Scheppingen J, Aronica E.
    Expert Rev Neurother; 2018 Mar 15; 18(3):185-201. PubMed ID: 29338461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.